Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-113-1803 long-term efgartigimod in primary immune thrombocytopenia
2024-511504-17-00Phase 3Completed
- Sponsor
- argenx
- Start
- May 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in immune thrombocytopenia (ITP), sponsored by argenx. Primary endpoints: Safety: frequency and severity of adverse events, Safety: vital signs and 1 more. Started May 2024; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2024-511504-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511504-17-00.